Business Context and Reporting Period
Company: Zentalis Pharmaceuticals, Inc. (ZNTL)
Filing Type: Form 8-K (Current Report)
Report Date: March 26, 2026
Reporting Period: Year ended December 31, 2025
This filing announces the Company's financial results for the full year 2025 and provides business updates. The detailed financial data and commentary are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not deemed "filed" under the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not explicitly stated in the Form 8-K cover page text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the year ended December 31, 2025, were announced.
Guidance, Outlook, and Risks
Management Commentary: The Company commented on "certain business updates" alongside the financial results, though the specific content of these updates is not detailed in the filing text.
Guidance and Risks: No specific forward-looking guidance, risk factors, contingencies, or unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2025 revenue, net loss, and cash burn figures.
- Verify the details of the "business updates" mentioned in the announcement.
- Confirm current cash runway and liquidity position as of December 31, 2025.
- Check for any new clinical trial milestones or regulatory developments referenced in the full press release.